Opioid-induced constipation: pathophysiology, clinical consequences, and management

Lalit Kumar, Chris Barker, Anton Emmanuel, Lalit Kumar, Chris Barker, Anton Emmanuel

Abstract

Although opioids offer potent analgesia for severe acute and chronic noncancer pain, adverse gastrointestinal effects potentially undermine their clinical utility. In particular, between 40% and 95% of patients develop opioid-induced constipation (OIC). Therefore, there is a consensus that patients should commence laxatives at the start of opioid therapy and continue throughout treatment. Nevertheless, laxatives are not routinely coprescribed with opioids. Even when concurrent laxatives are prescribed, approximately half the patients treated for OIC do not achieve the desired improvement. Moreover, laxatives do not target the underlying cause of OIC (opioid binding to the μ -receptors in the enteric system) and as such are not very effective at managing OIC. The failure of lifestyle modification and laxatives to treat adequately many cases of OIC led to the concurrent use of peripherally acting opioid antagonists (such as methylnaltrexone bromide and naloxone) to reduce the incidence of gastrointestinal adverse events without compromising analgesia. Judicious use of the various options to manage OIC should allow more patients to benefit from opioid analgesia. Therefore, this paper reviews the causes, consequences, and management of OIC to help clinicians optimise opioid analgesia.

Figures

Figure 1
Figure 1
Treatment pathway for opioid-induced constipation.

References

    1. Casati A, Sedefov R, Pfeiffer-Gerschel T. Misuse of medicines in the European Union: a systematic review of the literature. European Addiction Research. 2012;18:228–245.
    1. Alexander G, Kruszewski SP, Webster DW. Rethinking opioid prescribing to protect patient safety and public health. Journal of the American Medical Association. 2012;308:1865–1866.
    1. NICE. Opioids in Palliative Care: Safe and Effective Prescribing of Strong Opioids for Pain in Palliative Care of Adults Clinical Guideline 140. London, UK: NICE; 2012.
    1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional Bowel Disorders. Gastroenterology. 2006;130(5):1480–1491.
    1. Ueberall MA, Müller-Lissner S, Buschmann-Kramm C, Bosse B. The bowel function index for evaluating constipation in pain patients: definition of a reference range for a non- constipated population of pain patients. Journal of International Medical Research. 2011;39(1):41–50.
    1. Rentz AM, Yu R, Müller-Lissner S, Leyendecker P. Validation of the Bowel Function index to detect clinically meaningful changes in opioid-induced constipation. Journal of Medical Economics. 2009;12(4):371–383.
    1. McMillan SC. Assessing and managing opiate-induced constipation in adults with cancer. Cancer Control. 2004;11(3, supplement 1):3–9.
    1. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician. 2008;11(2):S105–S120.
    1. Holzer P. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neuroscience Letters. 2004;361(1–3):192–195.
    1. Mancini I, Bruera E. Constipation in advanced cancer patients. Supportive Care in Cancer. 1998;6(4):356–364.
    1. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112(3):372–380.
    1. Panchal SJ, Müller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. International Journal of Clinical Practice. 2007;61(7):1181–1187.
    1. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. The American Journal of Surgery. 2001;182(5):11S–18S.
    1. Thorpe DM. Management of opioid-induced constipation. Current pain and headache reports. 2001;5(3):237–240.
    1. Wald A. Management and prevention of fecal impaction. Current Gastroenterology Reports. 2008;10(5):499–501.
    1. Devulder J, Richarz U, Nataraja SH. Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain. Current Medical Research and Opinion. 2005;21(10):1555–1566.
    1. Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey. Journal of Opioid Management. 2009;5(3):137–144.
    1. Holmes S. Use of a modified symptom distress scale in assessment of the cancer patient. International Journal of Nursing Studies. 1989;26(1):69–79.
    1. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs. 2003;63(7):649–671.
    1. Müller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. The American Journal of Gastroenterology. 2005;100(1):232–242.
    1. Goodheart C, Leavitt S. Managing Opioid-Induced Constipation in Ambulatory-Care Patients. Glenview, Ill, USA: Pain Treatment Topics; 2006.
    1. Freedman MD, Schwartz HJ, Roby R, Fleisher S. Tolerance and efficacy of polyethylene glycol 3350/electrolyte solution versus lactulose in relieving opiate induced constipation: a double-blinded placebo-controlled trial. The Journal of Clinical Pharmacology. 1997;37(10):904–907.
    1. Ramkumar D, Rao SSC. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. The American Journal of Gastroenterology. 2005;100(4):936–971.
    1. Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut. 2011;60(2):209–218.
    1. Candy B, Jones L, Goodman ML, Drake R, Tookman A. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database of Systematic Reviews. 2011;(1)CD003448
    1. Ahmedzai SH, Nauck F, Bar-Sela G, Bosse B, Leyendecker P, Hopp M. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine. 2012;26(1):50–60.
    1. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. The New England Journal of Medicine. 2008;358(22):2332–2343.
    1. Relistor [package insert] Wyeth Pharmaceuticals, Philadelphia, Pa, USA, 2009.
    1. Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Current Medical Research and Opinion. 2008;24(12):3503–3512.
    1. Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. Journal of Pain. 2008;9(12):1144–1154.
    1. Sandner-Kiesling A, Leyendecker P, Hopp M, et al. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. International Journal of Clinical Practice. 2010;64(6):763–774.
    1. Löwenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opinion on Pharmacotherapy. 2009;10(4):531–543.
    1. Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. European Journal of Pain. 2009;13(1):56–64.
    1. Schmidt WK. Alvimopan (ADL 8-2698) is a novel peripheral opioid antagonist. The American Journal of Surgery. 2001;182(5):S27–S38.
    1. Webster L, Jansen JP, Peppin J, et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain. 2008;137(2):428–440.
    1. Irving G, Pénzes J, Ramjattan B, et al. A randomized, placebo-controlled phase 3 trial (study sb-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. Journal of Pain. 2011;12(2):175–184.
    1. Moss J, Rosow CE. Development of peripheral opioid antagonists: new insights into opioid effects. Mayo Clinic Proceedings. 2008;83(10):1116–1130.
    1. Adolor Corporation. 2008,
    1. Wong BS, Camilleri M. Lubiprostone for the treatment of opioid-induced bowel dysfunction. Expert Opinion on Pharmacotherapy. 2011;12(6):983–990.
    1. Sucampo Pharmaceuticals. .
    1. Ford AC, Brenner DM, Schoenfeld PS. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis. The American Journal of Gastroenterology. 2013;108:1566–1574.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere